KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
AcquisitionsAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Dividends Paid - CommonExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Resmed (RMD) Change in Accured Expenses (2016 - 2025)

Historic Change in Accured Expenses for Resmed (RMD) over the last 17 years, with Q4 2025 value amounting to $10.6 million.

  • Resmed's Change in Accured Expenses rose 15225.12% to $10.6 million in Q4 2025 from the same period last year, while for Dec 2025 it was $130.5 million, marking a year-over-year decrease of 424.54%. This contributed to the annual value of $91.0 million for FY2025, which is 2548.82% down from last year.
  • According to the latest figures from Q4 2025, Resmed's Change in Accured Expenses is $10.6 million, which was up 15225.12% from $7.6 million recorded in Q3 2025.
  • Resmed's 5-year Change in Accured Expenses high stood at $257.5 million for Q1 2021, and its period low was -$293.3 million during Q3 2021.
  • Over the past 5 years, Resmed's median Change in Accured Expenses value was $9.3 million (recorded in 2022), while the average stood at $16.3 million.
  • Over the last 5 years, Resmed's Change in Accured Expenses had its largest YoY gain of 3686242.42% in 2024, and its largest YoY loss of 239901.77% in 2024.
  • Resmed's Change in Accured Expenses (Quarter) stood at -$12.4 million in 2021, then tumbled by 39.38% to -$17.3 million in 2022, then tumbled by 99.02% to -$34.4 million in 2023, then soared by 112.28% to $4.2 million in 2024, then soared by 152.25% to $10.6 million in 2025.
  • Its Change in Accured Expenses stands at $10.6 million for Q4 2025, versus $7.6 million for Q3 2025 and $49.1 million for Q2 2025.